Ketamine is a versatile agent primarily utilized as a dissociative anesthetic, which acts by
blocking the excitatory receptor N-methyl-d-aspartate receptor (NMDA). It functions to inhibit …

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-
based antidepressant drugs are a primary line of treatment for this mental disorder, although …

The molecular mechanisms underlying major depressive disorder remain poorly
understood, and current antidepressant treatments have many shortcomings. The recent …

Major depressive disorder (MDD) is a devastating psychiatric disorder which exacts
enormous personal and social-economic burdens. Ketamine, an N-methyl-D-aspartate …

Ketamine is the prototype for a new generation of glutamate-based antidepressants that
rapidly alleviate depression within hours of treatment. Over the past decade, there has been …

Several recent studies have shown that a single intravenous subanesthetic dose of
ketamine, a NMDA receptor antagonist, exerts rapid antidepressant effects in patients with …

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-
resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of …

Newer antidepressants are needed for the many individuals with major depressive disorder
(MDD) that do not respond adequately to treatment and because of a delay of weeks before …

Introduction MDD represents a significant burden worldwide, and while a number of
approved treatments exist, there are high rates of treatment resistance and refractoriness …

Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …